Morgan Stanley Maintains Thermo Fisher Scientific(TMO.US) With Buy Rating, Cuts Target Price to $670

摩根士丹利维持赛默飞世尔(TMO.US)买入评级，下调目标价至670美元

moomoo资讯 · 2024/10/25 18:34 · 评级/大行评级

Morgan Stanley analyst Tejas Savant maintains $Thermo Fisher Scientific (TMO.US)$ with a buy rating, and adjusts the target price from $680 to $670.

According to TipRanks data, the analyst has a success rate of 38.0% and a total average return of -6.5% over the past year.

AnalystRecentRatingAutoNews_202477_20241024_0aa31e5c31006a4af6d3663dbda4792a9d6f493b_1729859404609072_mm_en

Furthermore, according to the comprehensive report, the opinions of $Thermo Fisher Scientific (TMO.US)$'s main analysts recently are as follows:

The company delivered financial results that met expectations in a period where anticipation was high. It is recognized for maintaining strong performance amidst a challenging demand landscape for tools, with limited insight into when demand might rebound.
While the company's Q3 earnings call presented a more upbeat outlook than the actual results, there remains a positive sentiment towards the stock. Momentum in the Life Sciences Solutions segment is noted, particularly in bioproduction, and the Laboratory Products and Biopharma Services segment appears to be insulated from the biotech slowdown.
The firm notes that Thermo Fisher's core growth is showing a consistent improvement quarter-over-quarter, with guidance suggesting a slight increase to around +2.5% in the fourth quarter. The expectations of a 5% core growth by 2025 also appear to be reasonable and justifiable. The firm appreciates Thermo Fisher's resilient profile and the flexibility provided by its balance sheet.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

摩根士丹利分析师Tejas Savant维持$赛默飞世尔 (TMO.US)$买入评级，并将目标价从680美元下调至670美元。

根据TipRanks数据显示，该分析师近一年总胜率为38.0%，总平均回报率为-6.5%。

AnalystRecentRatingAutoNews_202477_20241024_0aa31e5c31006a4af6d3663dbda4792a9d6f493b_1729859404609072_mm_sc

此外，综合报道，$赛默飞世尔 (TMO.US)$近期主要分析师观点如下：

在预期很高的时期，该公司公布的财务业绩符合预期。它因在充满挑战的工具需求格局中保持强劲的表现而受到认可，对需求何时可能反弹的了解有限。
尽管该公司的第三季度财报电话会议前景比实际业绩更为乐观，但对该股的情绪仍然乐观。生命科学解决方案板块的势头显而易见，尤其是在生物生产领域，实验室产品和生物制药服务板块似乎不受生物技术放缓的影响。
该公司指出，赛默飞世尔的核心增长同比持续改善，指导表明第四季度略有增长至+2.5％左右。到2025年核心增长5％的预期似乎也是合理和合理的。该公司对赛默飞世尔的弹性表现及其资产负债表提供的灵活性表示赞赏。

提示:

TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。

TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。

分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。

总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息

Morgan Stanley Maintains Thermo Fisher Scientific(TMO.US) With Buy Rating, Cuts Target Price to $670

Morgan Stanley Maintains Thermo Fisher Scientific(TMO.US) With Buy Rating, Cuts Target Price to $670

风险及免责提示

声明